RT Journal Article
SR Electronic
T1 Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.31.20042333
DO 10.1101/2020.03.31.20042333
A1 Ci Song
A1 Yan Wang
A1 Weiqin Li
A1 Bicheng Hu
A1 Guohua Chen
A1 Ping Xia
A1 Wei Wang
A1 Chaojun Li
A1 Zhibin Hu
A1 Xiaoyu Yang
A1 Bing Yao
A1 Yun Liu
YR 2020
UL http://medrxiv.org/content/early/2020/04/04/2020.03.31.20042333.abstract
AB Background As of March 11, 2020, the COVID-19 outbreak was declared as a pandemic. Expending our understanding of the transmission routes of the viral infection is crucial in controlling the outbreak. It is unclear whether the 2019 novel coronavirus (2019-nCoV) can directly infect the testes or male genital tract and be sexually transmitted from males.Methods From January 31 to March 14, 2020, 12 patients in recovery and one patient died of COVID-19 were included in this descriptive study. The clinical characteristics, laboratory findings, chest CT scans and outcome data were recorded. To examine whether there is sexual transmission from male, we employed realtime polymerase chain reaction testing (RT-PCR) to detect 2019-nCov in semen or testicular biopsy specimen.Findings The age range of the 12 patients in recovery was 22-38 years. None of the patients developed severe COVID-19 pneumonia. As of March 14, 2020, ten patients discharged from the hospital while the rest 2 had developed into recovery stage. All of the 12 patients in recovery tested negative for 2019-nCoV RNA in semen samples. Another patient aged 67 died in March 10, 2020, whose tissue sample via testicular biopsy was also tested negative for viral RNA.Conclusion No positive RT-PCR result was found in the semen or testicular biopsy specimen. The results from this study show no evidence of sexual transmission of 2019-nCov from males.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by the National Key Research and Development Program of China (2016YFC1000200, 2018YFC1004200); the State Key Program of National Natural Science of China (31530047); the National Natural Science Foundation of China (81903382, 81971374), the Natural Science Foundation of Jiangsu Province (BK20190652), China Postdoctoral Science Foundation (General Progaram, 2019M651900). Written informed consent was obtained from each enrolled patient.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe obtained the data from Wuhan No.1 Hospital and Jinling Hospital. The ownership of the data belongs to the two hospitals. Researchers who meet the criteria for access to confidential data can contact the corresponding authors to request the data.